News
03-08-2010, 08:00 AM
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
More... (http://www.news-medical.net/news/20100308/Positive-Phase-2-data-from-Nektar-Therapeutics-NKTR-102-study-in-women-with-platinum-resistant-ovarian-cancer.aspx)
More... (http://www.news-medical.net/news/20100308/Positive-Phase-2-data-from-Nektar-Therapeutics-NKTR-102-study-in-women-with-platinum-resistant-ovarian-cancer.aspx)